Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer
Recruiting · NCT06355050 · Observational (researchers observe without assigning treatment) · Lead sponsor: Jena University Hospital
View the official record on ClinicalTrials.gov →What this trial is about
In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively.
Who can take part
Inclusion criteria
- no androgen deprivation therapy within the last 2 months prior to RT
- good performance status (Eastern Cooperative Oncology Group, ECOG, 0/1)
- no secondary malignancy
Where it is running
1 location listed.
- Department of Radiotherapy and Radiation Oncology, Jena University Hospital - Jena, Germany